Anti-tumor necrosis factor alpha for retinal diseases: Current knowledge and future concepts

Journal of Ophthalmic and Vision Research

Volumn 7, Issue 1, 2012, Pages 39-44

  Mirshahi, Alireza ^a   Hoehn, René ^a   Lorenz, Katrin ^a   Kramann, Christina ^a   Baatz, Holger ^b,c  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Aurelios Eye Center   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Age related macular degeneration; Diabetic macular edema; Retinal vein occlusion; TNF ; Tumor necrosis factor; Uveitis

Indexed keywords

EID: 84860179184     PISSN: 20082010     EISSN: 2008322X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. McDermott MF. TNF and TNFR biology in health and disease. Cell Mol Biol (Noisy-le-grand) 2001;47:619-635.
2. Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB, et al. Therapeutic monoclonal antibodies in ophthalmology. Prog Retin Eye Res 2009;28:117-144.
3. Derevjanik NL, Vinores SA, Xiao WH, Mori K, Turon T, Hudish T, et al. Quantitative assessment of the integrity of the blood-retinal barrier in mice. Invest Ophthalmol Vis Sci 2002;43:2462-2467.
4. Prada J, Noelle B, Baatz H, Hartmann C, Pleyer U. Tumour necrosis factor alpha and interleukin 6 gene expression in keratocytes from patients with rheumatoid corneal ulcerations. Br J Ophthalmol 2003;87:548-550.
5. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004;13:1275-1293.
6. Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci 2001;42:1586-1591.
7. Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007;27:399-413.
8. Berger S, Savitz SI, Nijhawan S, Singh M, David J, Rosenbaum PS, et al. Deleterious role of TNFalpha in retinal ischemia-reperfusion injury. Invest Ophthalmol Vis Sci 2008;49:3605-3610.
9. Nagineni CN, Kommineni VK, William A, Detrick B, Hooks JJ. Regulation of VEGF expression in human retinal cells by cytokines: implications for the role of inflammation in age-related macular degeneration. J Cell Physiol 2012;227:116-126.
10. Joussen AM, Doehmen S, Le ML, Koizumi K, Radetzky S, Krohne TU, et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis 2009;15:1418-1428.
11. Pulido JS, Pulido JE, Michet CJ, Vile RG. More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a welldesigned trial. Retina 2010;30:1-5.
12. Pleyer U, Mackensen F, Winterhalter S, Stubiger N. Anti-TNF-α treatment for uveitis. Analysis of the current situation. Ophthalmologe 2011;108:13-20.
13. Sharma SM, Nestel AR, Lee RW, Dick AD. Clinical review: Anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience. Ocul Immunol Inflamm 2009;17:403-414.
14. Petropoulos IK, Vaudaux JD, Guex-Crosier Y. Anti- TNF-alpha therapy in patients with chronic noninfectious uveitis: the experience of Jules Gonin Eye Hospital. Klin Monbl Augenheilkd 2008;225:457-461.
15. Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol 2008;146:845-850.
16. Diaz-Llopis M, Garcia-Delpech S, Salom D, Udaondo P, Hernandez-Garfella M, Bosch-Morell F, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:351-361.
17. Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol 2005;139:537-540.
18. Sfikakis PP, Grigoropoulos V, Emfietzoglou I, Theodossiadis G, Tentolouris N, Delicha E, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, doubleblind, placebo-controlled, crossover, 32-week study. Diabetes Care 2010;33:1523-1528.
19. Bainbridge J. Refractory diabetic macular edema. J Ophthalmic Vis Res 2010;5:143-144.
20. Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009;4:e8158.
21. Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 2011;55:256-263.
22. Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan- American Collaborative Retina Study Group. Retina 2011;31:298-303.
23. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina 2010;30:71-80.
24. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular agerelated macular degeneration. Am J Ophthalmol 2009;147:825-830.